avapro has been researched along with Cardiomegaly in 13 studies
Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.
irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Compared with untreated controls, omapatrilat and I + H significantly attenuated hypertension [male control, 198." | 7.72 | Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. ( Beattie, E; Dominiczak, AF; Graham, D; Hamilton, C; Spiers, A, 2004) |
| "Cardiac hypertrophy is not only an adaptational state before heart failure but also is an independent risk factor for ischemia, arrhythmia, and sudden death." | 5.36 | The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin-angiotensin system in diet-induced hypercholesterolemic rats. ( Hu, D; Li, Y; Liu, N; Ren, L; Sheng, Z; Tang, R, 2010) |
| " Irbesartan and captopril significantly reduced systolic pressure and produced similar rightward shifts in the angiotensin I dose-response curve." | 5.30 | Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats. ( Carraway, JW; Holycross, BJ; McCune, SA; Park, S; Radin, MJ, 1999) |
| " After surgery, the AAB-induced hypertension (AABIH) rats were treated with losartan 40 mg/kg/day, candesartan 10 mg/kg/day, irbesartan 10 mg/kg/day per os for 16 weeks." | 3.79 | Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats. ( Inamdar, MN; Kulkarni, C; Kulkarni, KS; Moinuddin, G, 2013) |
| "Angiotensin-converting enzyme 2 (ACE2), a monocarboxypeptidase which metabolizes angiotensin II (Ang II) to generate Ang-(1-7), has been shown to prevent cardiac hypertrophy and injury but the mechanism remains elusive." | 3.79 | Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice. ( Gao, PJ; Jin, HY; Lu, L; Oudit, GY; Penninger, JM; Shang, QH; Song, B; Xu, YL; Zhang, ZZ; Zhong, JC; Zhou, T; Zhu, DL, 2013) |
| "To observe effects of angiotensin (Ang) II receptor antagonist (AT1) irbesartan and angiotensin-converting enzyme (ACE) inhibitor perindopril on rat myocardium calcineurin expression and sarcoplasmic reticulum Ca(2+)-ATPase activity in the model of pressure-overload cardiac hypertrophy." | 3.73 | Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca2+-ATPase activity in rat cardiac pressure-overload hypertrophy. ( Jiang, QJ; Mao, FF; Xu, G; Zhu, YF, 2006) |
| "Compared with untreated controls, omapatrilat and I + H significantly attenuated hypertension [male control, 198." | 3.72 | Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences. ( Beattie, E; Dominiczak, AF; Graham, D; Hamilton, C; Spiers, A, 2004) |
| "In the WT mice, Ang Ⅱ induced cardiac hypertrophy as well as vascular remodeling and perivascular fibrosis of the intramyocardial arteries and monocyte/macrophage infiltration in the heart (p＜0." | 1.42 | Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4. ( Fukai, T; Itoh, S; Matsuda, S; Matsuzaki, M; Murata, T; Umemoto, S; Yoshimura, K, 2015) |
| "Cardiac hypertrophy is not only an adaptational state before heart failure but also is an independent risk factor for ischemia, arrhythmia, and sudden death." | 1.36 | The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin-angiotensin system in diet-induced hypercholesterolemic rats. ( Hu, D; Li, Y; Liu, N; Ren, L; Sheng, Z; Tang, R, 2010) |
| "Thyroid hormone induces cardiac hypertrophy and preconditions the myocardium against ischemia reperfusion injury." | 1.33 | Blockade of angiotensin II type 1 receptor diminishes cardiac hypertrophy, but does not abolish thyroxin-induced preconditioning. ( Cokkinos, DV; Karageorgiou, H; Karamanoli, E; Moraitis, P; Mourouzis, C; Mourouzis, I; Paizis, I; Pantos, C; Tzeis, S, 2005) |
| " Thus, AT(1) blockade with irbesartan, at an oral daily dosage that gave a slight but significant reduction of systolic blood pressure, largely counteracts the development of myocyte hypertrophy and associated functional alterations." | 1.32 | Treatment with irbesartan counteracts the functional remodeling of ventricular myocytes from hypertensive rats. ( Cerbai, E; De Paoli, P; Lonardo, G; Mugelli, A; Sartiani, L, 2003) |
| "Post-MI hypertrophy was associated with substantial increases in the messenger RNA (mRNA) expression of atrial natriuretic peptide (ANP), but no significant changes in SERCA or PLB levels." | 1.30 | Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle. ( Ambrose, J; Giraud, GD; Greenberg, BH; Muldoon, L; Perkins, KD; Pribnow, DG, 1999) |
| " Irbesartan and captopril significantly reduced systolic pressure and produced similar rightward shifts in the angiotensin I dose-response curve." | 1.30 | Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats. ( Carraway, JW; Holycross, BJ; McCune, SA; Park, S; Radin, MJ, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Moinuddin, G | 1 |
| Inamdar, MN | 1 |
| Kulkarni, KS | 1 |
| Kulkarni, C | 1 |
| Zhang, ZZ | 1 |
| Shang, QH | 1 |
| Jin, HY | 1 |
| Song, B | 1 |
| Oudit, GY | 1 |
| Lu, L | 1 |
| Zhou, T | 1 |
| Xu, YL | 1 |
| Gao, PJ | 1 |
| Zhu, DL | 1 |
| Penninger, JM | 1 |
| Zhong, JC | 1 |
| Matsuda, S | 1 |
| Umemoto, S | 1 |
| Yoshimura, K | 1 |
| Itoh, S | 1 |
| Murata, T | 1 |
| Fukai, T | 1 |
| Matsuzaki, M | 1 |
| Ren, L | 1 |
| Li, Y | 2 |
| Tang, R | 1 |
| Hu, D | 1 |
| Sheng, Z | 1 |
| Liu, N | 1 |
| Eguchi, K | 1 |
| Kario, K | 1 |
| Shimada, K | 1 |
| Cerbai, E | 1 |
| De Paoli, P | 1 |
| Sartiani, L | 1 |
| Lonardo, G | 1 |
| Mugelli, A | 1 |
| Graham, D | 1 |
| Hamilton, C | 1 |
| Beattie, E | 1 |
| Spiers, A | 1 |
| Dominiczak, AF | 1 |
| Pantos, C | 1 |
| Paizis, I | 1 |
| Mourouzis, I | 1 |
| Moraitis, P | 1 |
| Tzeis, S | 1 |
| Karamanoli, E | 1 |
| Mourouzis, C | 1 |
| Karageorgiou, H | 1 |
| Cokkinos, DV | 1 |
| Jiang, QJ | 1 |
| Xu, G | 1 |
| Mao, FF | 1 |
| Zhu, YF | 1 |
| Ambrose, J | 1 |
| Pribnow, DG | 1 |
| Giraud, GD | 1 |
| Perkins, KD | 1 |
| Muldoon, L | 1 |
| Greenberg, BH | 1 |
| Carraway, JW | 1 |
| Park, S | 1 |
| McCune, SA | 1 |
| Holycross, BJ | 1 |
| Radin, MJ | 1 |
| Kawano, H | 1 |
| Cody, RJ | 1 |
| Graf, K | 1 |
| Goetze, S | 1 |
| Kawano, Y | 1 |
| Schnee, J | 1 |
| Law, RE | 1 |
| Hsueh, WA | 1 |
| Ortlepp, JR | 1 |
| Breuer, J | 1 |
| Eitner, F | 1 |
| Kluge, K | 1 |
| Kluge, R | 1 |
| Floege, J | 1 |
| Hollweg, G | 1 |
| Hanrath, P | 1 |
| Joost, HG | 1 |
1 review available for avapro and Cardiomegaly
| Article | Year |
|---|---|
[What is a good marker for better antihypertensive therapy in diabetic patients when coexisting with hypertension].
Topics: Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; | 2002 |
12 other studies available for avapro and Cardiomegaly
| Article | Year |
|---|---|
Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Benzimidazoles; Biphenyl Compounds; | 2013 |
Cardiac protective effects of irbesartan via the PPAR-gamma signaling pathway in angiotensin-converting enzyme 2-deficient mice.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Biphenyl Compounds; Cardiom | 2013 |
Angiotensin Ⅱ Activates MCP-1 and Induces Cardiac Hypertrophy and Dysfunction via Toll-like Receptor 4.
Topics: Adrenergic alpha-Agonists; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Bipheny | 2015 |
The inhibitory effects of rosiglitazone on cardiac hypertrophy through modulating the renin-angiotensin system in diet-induced hypercholesterolemic rats.
Topics: Angiotensin II; Animals; Biphenyl Compounds; Cardiomegaly; Cholesterol, Dietary; Hypercholesterolemi | 2010 |
Treatment with irbesartan counteracts the functional remodeling of ventricular myocytes from hypertensive rats.
Topics: Action Potentials; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiomegaly; Cell | 2003 |
Comparison of the effects of omapatrilat and irbesartan/hydrochlorothiazide on endothelial function and cardiac hypertrophy in the stroke-prone spontaneously hypertensive rat: sex differences.
Topics: Animals; Antihypertensive Agents; Biological Availability; Biphenyl Compounds; Blood Pressure; Carba | 2004 |
Blockade of angiotensin II type 1 receptor diminishes cardiac hypertrophy, but does not abolish thyroxin-induced preconditioning.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Biphenyl Compounds; Cardiomegaly; Irbesartan; Male | 2005 |
Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca2+-ATPase activity in rat cardiac pressure-overload hypertrophy.
Topics: Animals; Biphenyl Compounds; Calcineurin; Calcium-Transporting ATPases; Cardiomegaly; Disease Models | 2006 |
Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Biphe | 1999 |
Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 1999 |
Angiotensin II enhances integrin and alpha-actinin expression in adult rat cardiac fibroblasts.
Topics: Actinin; Age Factors; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antigens, CD; Antih | 2000 |
Inhibition of the renin-angiotensin system ameliorates genetically determined hyperinsulinemia.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensiv | 2002 |